NOCIL Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹316 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹27 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
NOCIL's Q3 FY26 performance reflects mixed signals with domestic volume strength offset by persistent export headwinds. Revenue from operations stood at Rs 316 crore, with 27 crore EBITDA translating to an 8.5% margin. The 9-month revenue of Rs 973 crore declined approximately 7.6% YoY from Rs 1,053 crore, reflecting the combined impact of H1 degrowth and export weakness. EBITDA margin compressed to 8.2% for 9M FY26 versus 9.8% in the prior year, driven by pricing pressure from import dumping and competitive headwinds. The anti-dumping investigations have received procedural extensions due to administrative restructuring at the DGTR, with findings now expected within 1.5-2 months. The TDQ antioxidant capacity expansion is ahead of schedule with trials planned H1 CY26, while new product commercialization is expected to contribute 10-12% of volumes by FY28. Management guided for 3-4% full-year volume growth in FY26 and double-digit volume growth in FY27, with approximately 150bps annual margin improvement expected from operational efficiency and new product ramp-up. Key risks include delayed anti-dumping outcomes, raw material price volatility, and continued export market uncertainty from tariff dynamics.
Colored figures show movement against the previous available record.
Guidance to track
- Despite H1 FY26 degrowth of -5% YoY, management expects Q4 recovery to drive full-year volume growth of 3-4%, with strong domestic momentum continuing into Q4.
- MD expects overall double-digit volume growth in FY27, driven by US tariff recovery (50% of lost volumes expected back within 2-3 months), India-EU FTA tailwinds, and new product ramp-up.
- TDQ antioxidant expansion at Dahej is ahead of original schedule, with production trials planned H1 CY26. Customer approvals expected during FY27 with volume ramp-up through FY28.
- Management targets at least 150bps annual EBITDA margin improvement through operational efficiency initiatives, new product mix, and improved capacity utilization, over the next 2-3-4 years.
Risks flagged
- Anti-dumping investigations against Chinese and EU imports have been delayed due to DGTR administrative restructuring. Findings were originally expected December 2025 but now expected within 1.5-2 months from Q3 call. Analyst Radha raised concern about potential routeing via Southeast Asia to circumvent duties — management clarified anti-dumping applies on country-of-origin basis, not supply route.
- While MD expects 50% of lost US volumes to return within 2-3 months, analyst Nidhi Dud flagged that European markets also showed demand weakness beyond tariff effects. Sequential export decline in Q3 and 8-9% YoY decline for 9M indicates structural demand softness in key export markets.
- Analyst Nidhi Dud specifically asked whether gross margins per kg had hit the lowest levels ever, even below Q2. Management acknowledged Q3 EBITDA per kg was at the lower end of the spectrum, despite cost savings of Rs 23 crore embedded in 9M results. Raw material prices have started uptick and management expects to pass through increases, but timing lag could compress near-term margins.
- New products expected to contribute 10-12% of total volumes at peak are in soft launch phase with slow ramp-up. MD explicitly stated FY27 will still be on the slower side, with FY28 being the year volumes are expected to accelerate — a 2-year timeline from initial launch with customer approval delays possible given large customer qualification cycles.
Key quotes
- We expect to end financial year 26 with a volume growth of 3 to 4% in spite of a minus 5% degrowth in H1 FI26 on a year-to-year basis.
- Roughly about 50% of that [lost US volumes] could come back to us within next 2 to 3 months.
- We are looking that at with all the initiatives over the next two to three years we expect at least on an annual basis an improvement of 150 basis points and plus or minus on an annual basis.
Research modules